SIENNA BIOPHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
SIENNA BIOPHARMACEUTICALS INC. - More news...
SIENNA BIOPHARMACEUTICALS INC. - More news...
- Sienna Biopharmaceuticals Announces Court Approval of Chapter 11 Bidding Procedures
- Sienna Biopharmaceuticals Announces Successful Appeal of Nasdaq Delisting Notice
- Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair
- Sienna Biopharmaceuticals Initiates Voluntary Chapter 11 Protection Proceeding
- Sienna Biopharmaceuticals Engages Cowen to Explore Financial and Strategic Alternatives
- Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
- Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
- Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
- Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
- Sienna Biopharmaceuticals to Present at BAML Health Care Conference
- Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results
- Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations
- Sienna Biopharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
- Sienna Biopharmaceuticals to Present at Cowen and Company Health Care Conference
- Sienna Biopharmaceuticals Prices Public Offering of Common Stock
- Sienna Biopharmaceuticals Announces Proposed Public Offering of Common Stock
- Sienna Biopharmaceuticals’ Novel Silver Photoparticle Technology SNA-001 Successfully Removes Light Hair When Used with Common Laser System
- Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference
- Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
- Sienna Biopharmaceuticals Announces Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) Demonstrated Significant Impact on Psoriasis in Phase 2b Study and Plans to Initiate Phase 3 Psoriasis Trials in Second Half of 2019
- Sienna Biopharmaceuticals® Reports Third Quarter 2018 Financial Results
